Literature DB >> 3239956

Paraneoplastic cerebellar degeneration: clinical-immunological correlations.

N E Anderson1, M K Rosenblum, J B Posner.   

Abstract

Four different antineuronal autoantibodies have been identified in 23 of 47 patients with paraneoplastic cerebellar degeneration (PCD). The most common, an antibody against 34- to 38-kDa and 62- to 64-kDa protein antigens in the cytoplasm of Purkinje cells, was found in 18 patients. It is a highly specific marker for a severe stereotypical subacute pancerebellar syndrome of truncal and appendicular ataxia, dysarthria, and nystagmus in women with cancer (usually ovarian or breast carcinoma). Different anti-Purkinje cell antibodies (APCA) were found in 2 other patients with PCD. With two possible exceptions, an APCA was not found in patients with other neurological diseases, with cancer not associated with neurological symptoms, or in normal subjects. Antibodies reactive with neuronal nucleoproteins were identified in 3 other patients with PCD: an antibody that recognized 35- to 40-kDa neuronal antigens was found in 2 women with small-cell lung carcinoma, while an antibody in a woman with breast carcinoma identified 53- to 61-kDa and 79- to 84-kDa antigens. Detection of an antineuronal antibody in a patient without known cancer should prompt a careful search for a tumor at a site appropriate to the antibody type.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3239956     DOI: 10.1002/ana.410240413

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  35 in total

1.  A follow up study of patients with paraneoplastic neurological disease in the United Kingdom.

Authors:  P M Candler; P E Hart; M Barnett; R Weil; J H Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

2.  Pursuing an occult carcinoma in a patient with subacute cerebellar degeneration and anticerebellar antibodies. Need for vigorous follow-up.

Authors:  J E Greenlee; H R Brashear; K A Jaeckle; A Geleris; K Jordan
Journal:  West J Med       Date:  1992-02

3.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

Authors:  Ami A Shah; Antony Rosen; Laura Hummers; Fredrick Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2010-09

4.  Unusual MRI abnormalities in anti-Yo positive "pure" paraneoplastic cerebellar degeneration.

Authors:  John C McHugh; Niall Tubridy; Conor D Collins; Michael Hutchinson
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

5.  Tendency for overdiagnosis of neuroborreliosis.

Authors:  R D'Alessandro; R Rinaldi; G Azzimondi; M Schiavina; P Pazzaglia
Journal:  Ital J Neurol Sci       Date:  1994-10

6.  Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer.

Authors:  L Sabater; L Bataller; A F Carpentier; M L Aguirre-Cruz; A Saiz; B Benyahia; J Dalmau; F Graus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-26       Impact factor: 10.154

7.  Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration.

Authors:  Markus Frings; Gerald Antoch; Philipp Knorn; Lutz Freudenberg; Ulrich Bier; Dagmar Timmann; Matthias Maschke
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

Review 8.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain.

Authors:  R B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 9.  Central nervous system toxicity from cancer treatment.

Authors:  Terri Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

10.  Paraneoplastic cerebellar degeneration with a circulating antibody against neurons and non-neuronal cells.

Authors:  H Tomimoto; J M Brengman; T Yanagihara
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.